PITTSBURGH, Feb. 26 /PRNewswire-FirstCall/ -- Mylan Inc. today announced the appointment of Patrick Vink as Senior Vice President in the new position of Global Head of Biologics. Mr. Vink will oversee Mylan's global biologics division and help develop the Company's strategy in this important growth area.

Mr. Vink comes to Mylan with 20 years of experience in the global pharmaceuticals industry including leadership roles at companies such as Sanofi, Biogen and Sandoz. Most recently, he was as an independent consultant and advisor to life sciences companies, venture capital and private equity investors and non-governmental organizations (NGOs). Prior to becoming a consultant, Mr. Vink served as the Global Head of Business Unit Biopharmaceuticals at Sandoz and as a member of Sandoz's Worldwide Executive Committee. In this position, he oversaw the technical and clinical development, manufacturing and regulatory affairs for biopharmaceutical products. In addition, he was responsible for manufacturing cooperation with other large biotech companies. Notably, while at Sandoz, Mr. Vink led the successful development and registration of the first bio-similar (bio-generic) biopharmaceutical in the United States and Europe, a landmark event for the pharmaceutical industry.

Prior to joining Sandoz, Mr. Vink served as Vice President of International Sales at Biogen and Associate Vice President, Cardiovascular- Thrombosis at Sanofi-Synthelabo.

Mylan Vice Chairman and CEO Robert J. Coury said, "As we have said for some time, Mylan is committed to delivering an appropriate global biologics strategy and this remains one of our key remaining strategic imperatives. Patrick's strong reputation and significant experience in this specialized field will be invaluable to this effort and ensure we are well-positioned in this space at market formation. We are thrilled to welcome him to Mylan."

Mr. Vink said, "I am extremely pleased to be joining Mylan, particularly at such an exciting time in the Company's development. I have been working with the Mylan team for some time as a consultant and have been very impressed with their leadership and commitment to excellence in every area in which they operate. There are significant opportunities for Mylan in the global bio- generics area, given its reputation for manufacturing and operational excellence and high quality products. I am confident that my expertise in the biologics field will produce a strong and competitive biologics platform for the Company that leverages its global commercial footprint."

Mr. Vink earned his doctorate of medicine from the University of Leiden in the Netherlands and an MBA from the William E. Simon School in Rochester, N.Y. He has also attended the Dutch Institute of Marketing in the Netherlands and postgraduate courses at Harvard University and Stanford University.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey, L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas. For more information about Mylan, please visit www.mylan.com.

CONTACT: Mike Laffin (Media), or Kris King (Investors), both for Mylan
Inc., +1-724-514-1813

Web site: http://www.mylan.com/